Morteza Salimian

Morteza Salimian

Auto-generated profile, based on publicly available information

Morteza Salimian

Department of Medical Laboratory, Kashan University of Medical Sciences and Health, Kashan, Iran

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
FKFarnaz Khodabakhsh
Farnaz Khodabakhsh
MSMorteza Salimian
Morteza Salimian
AMArdavan Mehdizadeh
Ardavan Mehdizadeh
MKMohammad Sadeq Khosravy
Mohammad Sadeq Khosravy
AVAlireza Vafabakhsh
Alireza Vafabakhsh
RCReza Ahangari Cohan
Reza Ahangari Cohan
Therapeutic fragmented antibodies show a poor pharmacokinetic profile that leads to frequent high-dose administration. In the current study, for the first time, a novel proline, alanine, serine (PAS) repeat sequence, called PAS#208, was designed to extend the plasma half-life of a nano-sized anti-Vascular Endothelial Growth Factor-A single-domain antibody. Polyacrylamide gel electrophoresis, circular dichroism, dynamic light scattering, and electrophoretic light scattering were used to assess the physicochemical properties of the newly designed PAS sequence. The effect of PAS#208 on the biological activity of a single-domain antibody was studied using an in vitro proliferation assay. The pharmacokinetic parameters including terminal half-life, the volume of distribution, elimination rate constant, and clearance were determined in mice model and compared to the native protein and PAS#1(200) sequence. The novel PAS repeat sequence showed comparable physicochemical, biological, and pharmacokinetic features to the previously reported PAS#1(200) sequence. The PAS#208 increased the hydrodynamic radius and decreased significantly the electrophoretic mobility of the native protein without any change in zeta potential. Surprisingly, the fusion of PAS#208 to the single-domain antibody increased the binding potency. In addition, it did not alter the biological activity and did not show any cytotoxicity on the normal cells. The PAS#208 sequence improved the terminal half-life (14-fold) as well as other pharmacokinetic parameters significantly. The simplicity as well as superior effects on half-life extension, make PAS#208 sequence as a novel sequence for in vivo pharmacokinetic enhancement of therapeutic fragmented antibodies. Significance Statement •In the current study, a new PAS sequence was developed that showed comparable physicochemical, biological, and pharmacokinetic features to the previously reported PAS#1(200) sequence. •The simplicity as well as superior effects on half-life extension, make PAS#208 sequence as a novel sequence for in vivo pharmacokinetic enhancement of recombinant small proteins.

11 April 2021 in Indian Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
EHElahe Seyed Hosseini
Elahe Seyed Hosseini
MZMarziyeh Alizadeh Zarei
Marziyeh Alizadeh Zarei
HKHamed Haddad Kashani
Hamed Haddad Kashani
MSMorteza Salimian
Morteza Salimian
NKNarjes Riahi Kashani
Narjes Riahi Kashani
HNHossein Nikzad
Hossein Nikzad

22 March 2013 in International Journal of Hyperthermia
Verified
Journal Article
Closed access
AAAkbar Aliasgharzadeh
Akbar Aliasgharzadeh
AGAhmad Gharehbaghian
Ahmad Gharehbaghian
ATAli Akbar Taherian
Ali Akbar Taherian
MGMehran Ghasemzadeh
Mehran Ghasemzadeh
MSMorteza Salimian
Morteza Salimian
Purpose: This study has been conducted to evaluate the effect of urea on aggregation responses of heat-treated platelets. Materials and methods: The urea was added to platelet-rich plasma (PRP) samples in final concentrations of 50 and 100 mM. PRP samples, with or without exogenous urea, were incubated at 37 °C, 39 °C and 41 °C for 90 min and then were stimulated with adenosine diphosphate (ADP) or epinephrine for measuring of platelet aggregation responses. The average reduction in aggregability of heat-treated samples with reference to mean value obtained for control samples treated at 37 °C was expressed as inhibition percentage. Results: Aggregation responses of the samples treated in the presence of 50 mM and 100 mM urea were significantly less inhibited by hyperthermia treatments compared with those treated without exogenous urea. Conclusion: The results indicate that the inhibitory effect of hyperthermia on platelet aggregation responses could be significantly modulated by urea.